CA2837261C - Novel processes for the preparation of prostaglandin amides - Google Patents

Novel processes for the preparation of prostaglandin amides Download PDF

Info

Publication number
CA2837261C
CA2837261C CA2837261A CA2837261A CA2837261C CA 2837261 C CA2837261 C CA 2837261C CA 2837261 A CA2837261 A CA 2837261A CA 2837261 A CA2837261 A CA 2837261A CA 2837261 C CA2837261 C CA 2837261C
Authority
CA
Canada
Prior art keywords
group
atom
formula
process according
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2837261A
Other languages
English (en)
French (fr)
Other versions
CA2837261A1 (en
Inventor
Gabor Havasi
Tibor Kiss
Iren Hortobagyi
Zsuzsanna Kardos
Istvan Laszlofi
Zoltan Bischof
Adam Bodis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU1100291A external-priority patent/HU230703B1/hu
Priority claimed from HU1100292A external-priority patent/HU231134B1/hu
Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority to CA3094762A priority Critical patent/CA3094762C/en
Publication of CA2837261A1 publication Critical patent/CA2837261A1/en
Application granted granted Critical
Publication of CA2837261C publication Critical patent/CA2837261C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
CA2837261A 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides Active CA2837261C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3094762A CA3094762C (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
HUP1100292 2011-06-02
HU1100291A HU230703B1 (hu) 2011-06-02 2011-06-02 Új eljárás prosztaglandin amidok előállítására
HU1100292A HU231134B1 (hu) 2011-06-02 2011-06-02 Eljárás a bimatoprost kémiailag stabil új kristályformájának előállítására
HUP1100291 2011-06-02
PCT/HU2012/000045 WO2012164324A1 (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3094762A Division CA3094762C (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Publications (2)

Publication Number Publication Date
CA2837261A1 CA2837261A1 (en) 2012-12-06
CA2837261C true CA2837261C (en) 2020-12-15

Family

ID=89990312

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2837261A Active CA2837261C (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides
CA3094762A Active CA3094762C (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides
CA3209613A Pending CA3209613A1 (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3094762A Active CA3094762C (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides
CA3209613A Pending CA3209613A1 (en) 2011-06-02 2012-05-25 Novel processes for the preparation of prostaglandin amides

Country Status (17)

Country Link
US (3) US9238621B2 (https=)
EP (1) EP2723714B1 (https=)
JP (3) JP6212485B2 (https=)
KR (3) KR102135550B1 (https=)
CN (4) CN103649047B (https=)
BR (3) BR112013030973B1 (https=)
CA (3) CA2837261C (https=)
ES (1) ES2636756T3 (https=)
HU (1) HUE033642T2 (https=)
IL (1) IL229647A (https=)
MX (1) MX341839B (https=)
PL (1) PL2723714T3 (https=)
PT (1) PT2723714T (https=)
RU (1) RU2618223C2 (https=)
TW (3) TWI632131B (https=)
WO (1) WO2012164324A1 (https=)
ZA (1) ZA201309357B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231203B1 (hu) 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
HU231214B1 (hu) * 2014-03-13 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás nagytisztaságú prosztaglandinok előállítására
WO2015199729A1 (en) * 2014-06-27 2015-12-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
HU231185B1 (hu) * 2017-07-11 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás Misoprostol előállítására és tisztítására
CN113548993B (zh) * 2021-09-01 2022-05-27 河北化工医药职业技术学院 一种卡前列素的制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954741A (en) * 1972-06-07 1976-05-04 Pfizer Inc. N-substituted prostaglandin carboxamides
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
HU171155B (hu) * 1973-04-30 1977-11-28 Pfizer Sposob poluchenija oksa-prostaglandinov
HU175889B (en) 1976-04-08 1980-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing lactol-alcohol derivatives
HU175217B (hu) * 1977-08-03 1980-06-28 Chinoin Gyogyszer Es Vegyeszet Novyj sposob poluchenija biciklicheskikh laktol-metil-ehfirov
HU178202B (en) * 1977-09-26 1982-03-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new,optically active and racemic bicyclic acetals and merkaptals
FR2550799B1 (fr) * 1983-08-17 1986-02-21 Commissariat Energie Atomique Compose marque par une enzyme, son procede de preparation et son utilisation en enzymoimmunologie
DE1300150T1 (de) * 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5359095A (en) 1990-08-08 1994-10-25 Pharmacia Ab Method for synthesis of prostaglandin derivatives
SE9002596D0 (sv) * 1990-08-08 1990-08-08 Pharmacia Ab A method for synthesis of prostaglandin derivatives
GB9025509D0 (en) * 1990-11-23 1991-01-09 Fujisawa Pharmaceutical Co New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
HU212570B (en) * 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JPH10298446A (ja) * 1997-04-25 1998-11-10 Mitsui Chem Inc 黄色建染染料の製造方法
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL159632A0 (en) * 2001-07-17 2004-06-01 Upjohn Co Process and intermediates to prepare latanoprost
DE10226942A1 (de) * 2002-06-17 2003-12-24 Symrise Gmbh & Co Kg Verwendung von Mandelsäurealkylamiden als Aromastoffe
NZ541824A (en) * 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
GB0329379D0 (en) 2003-12-19 2004-01-21 Johnson Matthey Plc Prostaglandin synthesis
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
AR071312A1 (es) * 2008-04-09 2010-06-09 Scinopharm Taiwan Ltd Proceso para la preparacion de analogos de prostaglandina y sus intermediarios
EP2135860A1 (en) * 2008-06-20 2009-12-23 Sandoz AG Improved process for the production of bimatoprost
GB0819182D0 (en) * 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
WO2010096123A2 (en) * 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
KR101736169B1 (ko) * 2009-03-16 2017-05-16 닛산 가가쿠 고교 가부시키 가이샤 저분자 겔화제로 이루어진 스프레이용 기재
JP6087147B2 (ja) * 2009-06-22 2017-03-01 ジョンソン、マッセイ、パブリック、リミテッド、カンパニーＪｏｈｎｓｏｎ Ｍａｔｔｈｅｙ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ プロスタグランジンの精製方法
GB0911000D0 (en) * 2009-06-25 2009-08-12 Givaudan Sa Compounds
KR101561171B1 (ko) * 2009-10-16 2015-10-19 카이맨 케미칼 컴파니 인코포레이티드 Ｆ-계열 프로스타글란딘의 제조 방법
JP5734302B2 (ja) * 2009-11-02 2015-06-17 上海天偉生物制薬有限公司 ビマトプロストの結晶およびその製造方法と用途
EP2496553A4 (en) 2009-11-05 2013-03-06 Biocon Ltd NEW METHOD FOR THE PRODUCTION OF PROSTAGLANDINES AND INTERMEDIATE PRODUCTS THEREOF
MX2012005968A (es) 2009-11-23 2012-08-15 Allergan Inc 7- [3,5 - dihidroxi - 2 - (3 - hidroxi - 5 - fenil - 1 - enil) - ciclopentil] - n - etil - hept - 5 - enamida (bmato prost) en la forma cristalina ii, metodos de preparacion y metodos para uso del mismo.
EP2495235B1 (en) * 2011-03-04 2015-08-05 Newchem S.p.A. Process for the synthesis of prostaglandins and intermediates thereof
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására

Also Published As

Publication number Publication date
US20140135503A1 (en) 2014-05-15
US9573892B2 (en) 2017-02-21
KR20200087871A (ko) 2020-07-21
BR122021008946B1 (pt) 2021-08-10
HUE033642T2 (en) 2017-12-28
JP6487410B2 (ja) 2019-03-20
TW201311629A (zh) 2013-03-16
CN103649047A (zh) 2014-03-19
BR122021008918B1 (pt) 2021-08-10
KR20190124804A (ko) 2019-11-05
TWI632131B (zh) 2018-08-11
US20160137602A1 (en) 2016-05-19
JP6212485B2 (ja) 2017-10-11
US9856213B2 (en) 2018-01-02
CN106316910A (zh) 2017-01-11
JP2014527026A (ja) 2014-10-09
CA3094762C (en) 2023-09-26
CA2837261A1 (en) 2012-12-06
PT2723714T (pt) 2017-08-18
WO2012164324A9 (en) 2014-01-09
RU2013158952A (ru) 2015-07-20
EP2723714B1 (en) 2017-06-21
JP2017075165A (ja) 2017-04-20
TW201708191A (zh) 2017-03-01
BR112013030973B1 (pt) 2021-08-10
CN106278982A (zh) 2017-01-04
CN106349138A (zh) 2017-01-25
WO2012164324A1 (en) 2012-12-06
TWI653222B (zh) 2019-03-11
CA3209613A1 (en) 2012-12-06
BR112013030973A2 (pt) 2016-08-16
PL2723714T3 (pl) 2018-02-28
JP6693859B2 (ja) 2020-05-13
KR102038048B1 (ko) 2019-10-30
US20160145207A1 (en) 2016-05-26
TW201708190A (zh) 2017-03-01
IL229647A (en) 2017-09-28
ES2636756T3 (es) 2017-10-09
EP2723714A1 (en) 2014-04-30
ZA201309357B (en) 2014-08-27
RU2618223C2 (ru) 2017-05-03
IL229647A0 (en) 2014-01-30
CN103649047B (zh) 2017-01-11
CA3094762A1 (en) 2012-12-06
JP2017061555A (ja) 2017-03-30
CN106278982B (zh) 2019-06-14
KR20140053941A (ko) 2014-05-08
MX2013014034A (es) 2015-06-17
US9238621B2 (en) 2016-01-19
MX341839B (es) 2016-09-05
TWI653223B (zh) 2019-03-11
KR102277188B1 (ko) 2021-07-15
BR112013030973A8 (pt) 2021-03-30
KR102135550B1 (ko) 2020-07-21

Similar Documents

Publication Publication Date Title
CA2837261C (en) Novel processes for the preparation of prostaglandin amides
KR102255357B1 (ko) 2-아미노-1,3-프로판디올 화합물 및 이의 염의 제조방법
JP5704763B2 (ja) トランス−４−アミノシクロペンタ−２−エン−１−カルボン酸誘導体の製造
CA2615832A1 (en) Method for producing nebivolol
JPH0446175A (ja) ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
HK1192556B (en) Novel processes for the preparation of prostaglandin amides
HK1192556A (en) Novel processes for the preparation of prostaglandin amides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170511

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241212

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250329

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401